11563 related articles for article (PubMed ID: 10757065)
1. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
[TBL] [Abstract][Full Text] [Related]
2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
3. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
4. Flavone acetic acid enhances accumulation of IL-2 activated NK cells within established metastases.
Kitson RP; Ohashi M; Brunson KW; Goldfarb RH
In Vivo; 1998; 12(6):593-7. PubMed ID: 9891222
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
[TBL] [Abstract][Full Text] [Related]
6. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
[TBL] [Abstract][Full Text] [Related]
7. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy.
Nannmark U; Johansson BR; Bryant JL; Unger ML; Hokland ME; Goldfarb RH; Basse PH
Cancer Res; 1995 Oct; 55(20):4627-32. PubMed ID: 7553640
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2.
Basse PH; Goldfarb RH; Herberman RB; Hokland ME
In Vivo; 1994; 8(1):17-24. PubMed ID: 8054506
[TBL] [Abstract][Full Text] [Related]
10. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
Berezhnaya NM; Vinnichuk YD; Belova OB
Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
Goldfarb RH; Ohashi M; Brunson KW; Kirii Y; Kotera Y; Basse PH; Kitson RP
Anticancer Res; 1998; 18(3A):1441-6. PubMed ID: 9673353
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
13. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
14. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis.
Johansson BR; Unger ML; Albertsson P; Casselbrant A; Nannmark U; Hokland M
Nat Immun; 1996-1997; 15(2-3):87-97. PubMed ID: 9162267
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
Da Costa ML; Redmond HP; Bouchier-Hayes DJ
J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
17. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.
Takashima K; Fujiwara H; Inada S; Atsuji K; Araki Y; Kubota T; Yamagishi H
Anticancer Res; 2006; 26(5A):3327-32. PubMed ID: 17094448
[TBL] [Abstract][Full Text] [Related]
18. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.
Grundy MA; Zhang T; Sentman CL
Cancer Immunol Immunother; 2007 Aug; 56(8):1153-61. PubMed ID: 17160409
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
